Celsion Announces Common Stock Purchase Agreement with Lincoln Park Capital and Provides Updates on OVATION 2 Study
08 sept. 2020 08h35 HE
|
Celsion CORP
Agreement Includes 1 Million Shares Purchased at 28% Market Premium LAWRENCEVILLE, N.J, Sept. 08, 2020 (GLOBE NEWSWIRE) -- Celsion Corporation (NASDAQ: CLSN), an oncology drug development company,...
Celsion Corporation Restructures its Strategic Loan Facility
02 sept. 2020 08h00 HE
|
Celsion CORP
Completes New $5 Million Loan Agreement with Market Competitive Terms and Debt Reduction Consistent with Celsion’s Capitalization New Agreement Ensures A Strong Balance Sheet and Additional...
Celsion Corporation to Hold Second Quarter 2020 Financial Results and Business Update Conference Call on Friday, August 14, 2020
07 août 2020 08h30 HE
|
Celsion CORP
LAWRENCEVILLE, N.J, Aug. 07, 2020 (GLOBE NEWSWIRE) -- Celsion Corporation (NASDAQ: CLSN) announced today that the Company will host a conference call to discuss financial results for the second...
Celsion Corporation to Continue Following Patients in Phase III OPTIMA Study for Overall Survival
04 août 2020 08h30 HE
|
Celsion CORP
Ongoing Analysis of Unblinded Study Data Suggests Data Maturity May be at Issue Cohort of 26 Consecutive Patient Deaths Differs Substantially from Predicted Behavior and from the Balance of the...
Celsion Corporation Initiates Phase II OVATION 2 Study of GEN-1 in Advanced Ovarian Cancer
27 juil. 2020 08h30 HE
|
Celsion CORP
Promising Translational and Clinical Findings Support the Randomized Trial in Newly Diagnosed Patients Non-Viral Nanoparticle Delivery System, TheraPlas Platform, Demonstrates Potential for...
Celsion Corporation to Hold Conference Call to Discuss OPTIMA Study on Wednesday, July 15, 2020 at 11:00 a.m. Eastern Time
14 juil. 2020 08h30 HE
|
Celsion CORP
LAWRENCEVILLE, N.J., July 14, 2020 (GLOBE NEWSWIRE) -- Celsion Corporation (NASDAQ: CLSN) will host a conference call and webcast on Wednesday, July 15 at 11:00 a.m. Eastern time to discuss its...
Celsion Corporation Receives Recommendation from Independent Data Monitoring Committee to Consider Stopping the Phase III OPTIMA Study
13 juil. 2020 08h30 HE
|
Celsion CORP
Recommendation Based on DMC’s Finding Following the Second Pre-Planned Interim Analysis that the OPTIMA Study is Unlikely to Meet its Primary Efficacy Endpoint of Overall Survival Celsion...
Celsion Affirms July Timing for Second Interim Analysis of the Phase III OPTIMA Study of ThermoDox® in Primary Liver Cancer
25 juin 2020 08h00 HE
|
Celsion CORP
LAWRENCEVILLE, N.J, June 25, 2020 (GLOBE NEWSWIRE) -- Celsion Corporation (NASDAQ: CLSN), an oncology drug-development company, today affirmed that the independent Data Monitoring Committee (iDMC)...
Celsion Corporation Announces Closing of Public Offering of Common Stock
24 juin 2020 16h15 HE
|
Celsion CORP
Lawrenceville, NJ, June 24, 2020 (GLOBE NEWSWIRE) -- Celsion Corporation (NASDAQ: CLSN), an oncology drug development company, today announced the closing of its previously announced public offering...
Celsion Corporation Announces Pricing of $10 Million Underwritten Offering of Common Stock
22 juin 2020 15h00 HE
|
Celsion CORP
Lawrenceville, NJ, June 22, 2020 (GLOBE NEWSWIRE) -- Celsion Corporation (NASDAQ: CLSN), an oncology drug development company, today announced the entry into an underwriting agreement relating to...